United gets rights to Samumed's IPF compound

Samumed LLC (San Diego, Calif.) granted United Therapeutics Corp. (NASDAQ:UTHR) exclusive, U.S. and Canadian rights to idiopathic pulmonary fibrosis candidate SM04646, a Wnt signaling pathway inhibitor.

Samumed will receive $10 million up front, and is eligible for up to $340 million in milestones, plus royalties up to the low, double digits. ...